Kyverna Therapeutics/$KYTX

1D1W1MYTD1Y5YMAX

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Ticker
$KYTX
Sector
Health
Primary listing
NASDAQ
Employees
149
Headquarters
EmeryVille, United States
Website
kyvernatx.com

KYTX Metrics

BasicAdvanced
$422M
-
-$2.88
1.94
-

What the Analysts think about KYTX

Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
Analyst projections of the future price of Kyverna Therapeutics stock.

Bulls say / Bears say

The KYSA-8 registrational study in stiff-person syndrome produced statistically significant improvements across its primary and secondary endpoints, including reversal of disability after one dose. No high-grade CRS or ICANS was observed, which supports a potentially more manageable safety profile for autoimmune use. (Kyverna Therapeutics)
Updated KYSA-6 data in generalised myasthenia gravis showed deep clinical responses that remained durable through one year, including meaningful reductions in MG-ADL and QMG scores. This supports the possibility that miv-cel could address a larger indication than stiff-person syndrome with a one-off treatment. (Kyverna Therapeutics)
Kyverna has started its rolling BLA for stiff-person syndrome, filed the CMC module and secured a commercial supply agreement with ElevateBio. The company is targeting completion of the filing in Q4 2026 and a potential 2027 launch, while RMAT status could support an accelerated review. (Kyverna Therapeutics, ElevateBio)
The investment still depends on important unproven follow-through: as of September, one-year SPS data was still an imminent milestone and the BLA was not due to be completed until Q4 2026. Durability, regulatory acceptance and confirmation in the larger gMG Phase 3 trial therefore remain key risks. (Kyverna Therapeutics, StockAnalysis)
Kyverna remains loss-making and used $81.9 million of cash in operations in the first half of 2026, leaving $199.4 million in cash and marketable securities at 30 June. Management's runway into 2028 depends on additional loan availability and ATM capacity, so further borrowing or equity issuance could dilute shareholders or increase financing pressure. (Kyverna Therapeutics)
Commercial scale-up is not yet proven for an autologous CAR-T product: Kyverna relies on third-party manufacturing and its ElevateBio agreement includes minimum order commitments in specified periods and after approval. That creates execution and fixed-cost risk if demand, manufacturing throughput or launch timing falls short of plan. (StockTitan, StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 20 Sept 2026.

KYTX Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

KYTX Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing KYTX

AllUSDGBPEUR
Funds
Fund name
Fund size
$KYTX weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.03%
iShares Nasdaq US Biotechnology£BTEK
£865M0.03%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
SPDR Russell 2000 US Small Cap£R2SC
£4.1B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.